These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27418444)

  • 81. Comparison the efficacy of vaginal progesterone
    Alavi A; Ranjbar A; Atighpoor F; Zare S
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7438-7444. PubMed ID: 34470137
    [TBL] [Abstract][Full Text] [Related]  

  • 82. PROLONG Clinical Study Protocol: Hydroxyprogesterone Caproate to Reduce Recurrent Preterm Birth.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck T; Miller HS; Das AF; Birch R; Jozwiakowski MJ
    Am J Perinatol; 2018 Oct; 35(12):1228-1234. PubMed ID: 29702708
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial.
    Shaamash AH; Ali MK; Attyia KM
    J Obstet Gynaecol; 2020 Jul; 40(5):633-638. PubMed ID: 31670998
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.
    Manuck TA; Lai Y; Meis PJ; Dombrowski MP; Sibai B; Spong CY; Rouse DJ; Durnwald CP; Caritis SN; Wapner RJ; Mercer BM; Ramin SM
    Am J Obstet Gynecol; 2011 Aug; 205(2):135.e1-9. PubMed ID: 21600550
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections.
    Haidar ZA; Moussa HN; Hosseini Nasab S; Sibai BM
    J Matern Fetal Neonatal Med; 2017 Dec; 30(24):2926-2932. PubMed ID: 27921517
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
    Megli CJ; Hauspurg A; Venkataramanan R; Caritis SN
    Am J Perinatol; 2023 Oct; 40(14):1585-1589. PubMed ID: 34784615
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
    Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
    Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy.
    Tsur A; Leonard SA; Kan P; Datoc IA; Girsen AI; Shaw GM; Stevenson DK; El-Sayed YY; Druzin ML; Blumenfeld YJ
    Am J Perinatol; 2023 Aug; 40(11):1158-1162. PubMed ID: 37100422
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.
    Wang X; Garcia SM; Kellom KS; Boelig RC; Matone M
    Am J Perinatol; 2023 Dec; 40(16):1770-1780. PubMed ID: 34784617
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
    Romero J; Rebarber A; Saltzman DH; Schwartz R; Peress D; Fox NS
    Am J Obstet Gynecol; 2012 Jul; 207(1):51.e1-5. PubMed ID: 22595378
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate.
    Durnwald CP; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Varner MW; Malone FD; Mercer BM; Thorp JM; Sorokin Y; Carpenter MW; Lo J; Ramin SM; Harper M; Spong CY;
    J Matern Fetal Neonatal Med; 2010 Dec; 23(12):1360-4. PubMed ID: 20441408
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women.
    Caritis SN; Dodeja P; Sharma S; Zhao W; Venkataramanan R
    Am J Obstet Gynecol; 2024 Apr; ():. PubMed ID: 38670444
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cervical stitch (cerclage) in combination with other treatments for preventing spontaneous preterm birth in singleton pregnancies.
    Eleje GU; Eke AC; Ikechebelu JI; Ezebialu IU; Okam PC; Ilika CP
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012871. PubMed ID: 32970845
    [TBL] [Abstract][Full Text] [Related]  

  • 96. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.
    Berghella V; Figueroa D; Szychowski JM; Owen J; Hankins GD; Iams JD; Sheffield JS; Perez-Delboy A; Wing DA; Guzman ER;
    Am J Obstet Gynecol; 2010 Apr; 202(4):351.e1-6. PubMed ID: 20350641
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM; Istwan NB; Palmer B; Stanziano GJ
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [TBL] [Abstract][Full Text] [Related]  

  • 99. 17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.
    Deeks ED
    Paediatr Drugs; 2011 Oct; 13(5):337-45. PubMed ID: 21888448
    [TBL] [Abstract][Full Text] [Related]  

  • 100. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
    Grobman WA; Thom EA; Spong CY; Iams JD; Saade GR; Mercer BM; Tita AT; Rouse DJ; Sorokin Y; Wapner RJ; Leveno KJ; Blackwell S; Esplin MS; Tolosa JE; Thorp JM; Caritis SN; Van Dorsten JP;
    Am J Obstet Gynecol; 2012 Nov; 207(5):390.e1-8. PubMed ID: 23010094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.